SOPHiA GENETICS SA Ordinary Shares (SOPH) is a publicly traded Healthcare sector company. As of May 20, 2026, SOPH trades at $4.77 with a market cap of $336.70M and a P/E ratio of 0.00. SOPH moved +3.42% today. Year to date, SOPH is +5.87%; over the trailing twelve months it is +69.10%. Its 52-week range spans $2.58 to $5.70. Analyst consensus is strong buy with an average price target of $7.50. Rallies surfaces SOPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
SOPHiA GENETICS Partners with Synnovis to Deliver 7,000 UK Liquid Biopsies Annually: Synnovis and SOPHiA GENETICS launched the MSK-ACCESS® liquid biopsy test powered by SOPHiA DDM™, supporting about 400 UK lung and breast cancer patients monthly and accelerating targeted therapies by up to two weeks. The rollout aims to process 7,000 annual tests—roughly one third of England’s ctDNA screenings—under NHS England’s blood test-first program.
| Metric | Value |
|---|---|
| Price | $4.77 |
| Market Cap | $336.70M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.70 |
| 52-Week Low | $2.58 |
| Volume | 56.05K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
4 analysts cover SOPH: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.50.